By Counterforce Health Team in Opdivo (nivolumab) —

How to Get Opdivo (Nivolumab) Covered by Humana in Ohio: Prior Authorization, Appeals & Exception Strategies

Quick Answer: Opdivo (nivolumab) requires prior authorization from Humana in Ohio, with approval typically taking 72 hours (24 hours expedited). Success depends on documenting FDA-approved indication, biomarker testing, prior therapy failures, and medical necessity. If denied, you have 65 days to appeal internally, then 180 days for Ohio external review. Start by having your oncologist submit PA with complete clinical documentation through Humana's provider portal.

Table of Contents

When Alternatives Make Sense

Before pursuing Opdivo (nivolumab) specifically, consider whether Humana's formulary alternatives might be appropriate for your cancer type. Alternatives make sense when:

  • Step therapy is required: Humana may require trying a preferred PD-1 inhibitor first
  • Biomarker requirements differ: Some alternatives have different PD-L1 testing thresholds
  • Combination regimens: Your treatment plan includes drugs where alternatives are better established
  • Access timing: Formulary drugs often have faster approval timelines

However, alternatives may not be suitable if you've previously failed or had adverse reactions to similar immunotherapies, or if your specific cancer subtype responds better to Opdivo based on clinical data.

Typical Formulary Alternatives

PD-1/PD-L1 Inhibitors

Keytruda (pembrolizumab) is often Humana's preferred PD-1 inhibitor for many indications, including:

  • First-line metastatic NSCLC (with PD-L1 ≥50%)
  • Melanoma (adjuvant and metastatic settings)
  • MSI-high/dMMR tumors (tumor-agnostic indication)

Libtayo (cemiplimab) may be covered for:

  • Advanced cutaneous squamous cell carcinoma
  • Certain NSCLC indications

Targeted Therapy Alternatives

Depending on your cancer type and biomarkers:

  • EGFR inhibitors (erlotinib, osimertinib) for EGFR-positive NSCLC
  • ALK inhibitors (crizotinib, alectinib) for ALK-positive NSCLC
  • BRAF inhibitors (vemurafenib, dabrafenib) for BRAF-positive melanoma

Considerations for Each Alternative

Drug Pros Cons Testing Required
Keytruda Broad indications, often preferred tier May require PD-L1 testing PD-L1 for some indications
Libtayo Good for specific squamous cancers Limited indications Varies by indication
Targeted therapies High response rates in biomarker-positive Only for specific mutations Genomic testing required

Coverage Requirements at a Glance

Requirement Details Source
Prior Authorization Required for all PD-1 inhibitors Humana PA List
Formulary Tier Specialty Tier 4/5 Humana Drug List Tool
Step Therapy May be required through preferred agent Humana Coverage Policies
Site of Care Outpatient infusion center (Part B coverage) CMS Part B Guidelines
Appeal Deadline 65 days from denial notice Humana Appeals Process
External Review 180 days after final internal denial Ohio Department of Insurance

Step-by-Step: Fastest Path to Approval

1. Verify Coverage and Requirements

Who: Patient or clinic staff
Action: Check Humana's drug list tool for Opdivo tier and restrictions
Timeline: Same day

2. Gather Clinical Documentation

Who: Oncologist and clinic staff
Documents needed:

  • Pathology reports confirming cancer diagnosis
  • Staging and imaging studies
  • Previous treatment history with outcomes
  • Biomarker testing results (PD-L1, MSI status if applicable)
  • Performance status assessment Timeline: 1-3 days

3. Submit Prior Authorization

Who: Prescribing physician
Method: Humana provider portal or fax to 1-877-486-2621
Include: Medical necessity letter with all supporting documentation
Timeline: Submit within 24-48 hours of gathering documents

4. Request Expedited Review if Appropriate

Who: Physician
Criteria: Disease progression threatens health if treatment delayed
Timeline: 24-hour decision vs. 72-hour standard review

5. Follow Up on Decision

Who: Patient or clinic
Action: Contact Humana at 1-800-457-4708 to confirm receipt and timeline
Timeline: Within 2-3 business days of submission

6. Prepare for Potential Appeal

Who: Patient and physician
Action: If denied, immediately begin gathering additional evidence for appeal
Timeline: Must appeal within 65 days of denial notice

Medical Necessity Documentation

Clinician Corner: Strong medical necessity letters significantly improve approval rates. Include these key elements:

Required Clinical Elements

  1. Specific cancer diagnosis with ICD-10 code and staging
  2. FDA-approved indication or NCCN guideline support
  3. Biomarker results supporting Opdivo use (PD-L1 expression, MSI status)
  4. Prior treatment failures with specific drugs, doses, and reasons for discontinuation
  5. Performance status (ECOG 0-2 typically required)
  6. Treatment goals and expected duration

Supporting Evidence to Include

  • Pathology reports confirming diagnosis and molecular features
  • Imaging studies showing disease extent and progression
  • Laboratory values demonstrating adequate organ function
  • Previous therapy records with response assessment and toxicity documentation

Key Guidelines to Reference

  • FDA prescribing information for approved indications
  • NCCN Guidelines for cancer-specific treatment algorithms
  • Professional society recommendations (ASCO, ESMO)

Exception Strategy for Non-Formulary Coverage

If Opdivo is not covered or requires step therapy, request a formulary exception by demonstrating:

Medical Necessity Criteria

  • Formulary alternatives would be less effective for your specific cancer type
  • Previous adverse reactions to covered alternatives
  • Contraindications to step therapy requirements
  • Biomarker profile specifically supports Opdivo over alternatives

Documentation Strategy

Include peer-reviewed studies showing Opdivo's superiority in your clinical scenario, such as:

  • Comparative effectiveness data for your cancer type
  • Biomarker-driven treatment selection studies
  • Safety profiles supporting Opdivo over alternatives

When preparing your exception request, Counterforce Health can help streamline the process by identifying the specific denial reasons and crafting targeted, evidence-backed appeals that align with Humana's own coverage criteria.

Appeals Playbook for Ohio

Internal Appeals with Humana

Level 1: Standard Redetermination

  • Deadline: 65 days from denial notice
  • Timeline: 7 days for decision
  • How to file: Humana member portal or written request
  • Required: Medical records, physician letter supporting medical necessity

Expedited Internal Appeal

  • When appropriate: Delay would seriously jeopardize health
  • Timeline: 72 hours for decision
  • Documentation: Physician statement of urgency required

External Review Through Ohio

After exhausting internal appeals, Ohio residents can request external review:

Eligibility: Medical necessity denials (not contractual exclusions)
Deadline: 180 days from final internal denial
How to file: Submit request through Humana, which notifies Ohio Department of Insurance
Timeline: 30 days standard, 72 hours expedited
Contact: Ohio Department of Insurance at 1-800-686-1526

Note: External review decisions are binding on Humana if overturned in your favor.

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
"Not medically necessary" Demonstrate disease severity and failed alternatives Treatment timeline, imaging, prior therapy records
"Experimental/investigational" Cite FDA approval and guidelines FDA label, NCCN guidelines, peer-reviewed studies
"Step therapy required" Document contraindications to preferred drugs Allergy records, previous adverse events, drug interactions
"Off-label use" Show compendial support NCCN guidelines, drug compendia citations
"Quantity limits exceeded" Justify dosing based on weight/renal function Clinical notes supporting dosing rationale

Switching Between Immunotherapies

If you need to switch from another PD-1 inhibitor to Opdivo:

Safety Considerations

  • Washout period: Generally not required between PD-1 inhibitors
  • Monitoring: Continue surveillance for immune-related adverse events
  • Documentation: Record reason for switch (progression, toxicity, access)

Coordination Steps

  1. Notify oncology team of insurance-driven switch needs
  2. Coordinate infusion scheduling with new drug availability
  3. Update monitoring protocols if different from previous agent
  4. Document clinical rationale for insurance and medical records

Research shows that switching between pembrolizumab and nivolumab is generally safe and effective, with similar response rates and toxicity profiles.

Re-trying for Opdivo Later

If initially denied and using an alternative:

Document Everything During Alternative Treatment

  • Response assessment at each evaluation
  • Toxicity events with grades and management
  • Quality of life impacts affecting treatment continuation
  • Disease progression patterns and timing

Resubmission Strategy

  • New clinical data supporting Opdivo specifically
  • Treatment failure documentation with alternative therapy
  • Updated guidelines or biomarker information
  • Peer-reviewed evidence published since initial denial
From our advocates: We've seen cases where documenting inadequate response to step therapy drugs (even partial responses) can support later approval for the originally requested agent. Keep detailed records of treatment response, side effects, and quality of life measures throughout any required alternative therapy.

Frequently Asked Questions

How long does Humana prior authorization take for Opdivo in Ohio?
Standard review takes 72 hours, expedited review 24 hours. Humana's PA timelines are consistent across Ohio.

What if Opdivo isn't on my Humana formulary?
Request a formulary exception through your physician with medical necessity documentation. The process is the same as prior authorization but requires stronger justification.

Can I request expedited review for cancer treatment?
Yes, if your physician documents that delay would seriously jeopardize your health or ability to regain maximum function.

Does step therapy apply if I failed similar drugs outside Ohio?
Previous treatment failures should be documented and submitted with your PA request. Out-of-state treatment records are valid evidence.

Who pays for Opdivo - Part B or Part D?
Opdivo infusions are typically covered under Medicare Part B (medical benefit) since they're administered in clinical settings.

What happens if external review upholds the denial?
The external review decision is final for the insurance process, but you retain rights to file regulatory complaints or seek other remedies.

How can I get help with the appeals process in Ohio?
Contact the Ohio Department of Insurance Consumer Services at 1-800-686-1526 for assistance with appeals and external review.

Are there financial assistance programs for Opdivo?
Bristol Myers Squibb offers patient assistance programs. CenterWell Specialty Pharmacy can help identify and apply for manufacturer assistance and foundation grants.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan details, medical circumstances, and current policies. Always consult with your healthcare provider and insurance representative for guidance specific to your situation.

For additional help navigating insurance appeals in Ohio, contact the Ohio Department of Insurance Consumer Services at 1-800-686-1526.

The appeals process can be complex, but Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed responses that address payers' specific concerns and criteria.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.